Increased sensitivity to stress in spontaneous recurrence of methamphetamine psychosis: Noradrenergic hyperactivity with contribution from dopaminergic hyperactivity

Journal of Clinical Psychopharmacology

Volumn 20, Issue 2, 2000, Pages 165-174

  Yui, Kunio ^a,b,d   Goto, Kimihiko ^c   Ikemoto, Shigenori ^b   Ishiguro, Takeo ^b   Kamata, Yoshinori ^b  

^a Ministry of Justice   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

^c NIPPON VETERINARY AND LIFE SCIENCE UNIVERSITY   (Japan)

^d NONE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3 O METHYLDOPAMINE; CHLORPROMAZINE; DOPAMINE; HALOPERIDOL; METHAMPHETAMINE; MONOAMINE; THIORIDAZINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; FEAR; HUMAN; HUMAN CELL; HUMAN TISSUE; NORADRENERGIC SYSTEM; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSYCHOSIS; STRESS;

ADULT; AROUSAL; BRAIN; CENTRAL NERVOUS SYSTEM STIMULANTS; DOPAMINE; FEMALE; HUMANS; LIFE CHANGE EVENTS; MENTAL RECALL; METHAMPHETAMINE; NOREPINEPHRINE; PRISONERS; PSYCHOSES, SUBSTANCE-INDUCED; RECURRENCE; STRESS, PSYCHOLOGICAL;

EID: 0034085160     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-200004000-00008     Document Type: Article

References (44)

1. Sato M, Chen CC, Akiyama K, Otsuki S. Acute exacerbation of paranoid psychotic state after long-term abstinence in patients with previous methamphetamine psychosis. Biol Psychiatry 1983;18:429-40.
2. Yui K, Goto K, Ikemoto S, Ishiguro T. Methamphetamine psychosis: spontaneous recurrence of paranoid-hallucinatory states and monoamine neurotransmitter function. J Clin Psychopharmacol 1997;17:34-43.
3. Petty F, Chae YI, Kramer G, Jordan S, Wilson L. Learned helplessness sensitizes hippocampal norepinephrine to mild restress. Biol Psychiatry 1994;35:903-8.
4. Cassens G, Roffman M, Kuruc A, Orsulak PJ, Schildkraut JJ. Alterations in brain norepinephrine metabolism induced by environmental stimuli previously paired with inescapable shock. Science 1980;209:1138-9.
5. Southwick SM, Krystal JH, Morgan CA, Johnson D, Nagy LM, Nicolaou A, Heninger GR, Charney DS. Abnormal noradrenergic function in posttraumatic stress disorder. Arch Gen Psychiatry 1993;50:266-74.
6. van der Kolk BA, Fisler R. Dissociation and the fragmentary nature of traumatic memories: overview and exploratory study. J Trauma Stress 1995;8:505-25.
7. Robinson TE, Becker JB, Young EA, Akil H, Castaneda E. The effects of footshock stress on regional brain dopamine metabolism and pituitary β-endorphin release in rats previously sensitized to amphetamine. Neuropharmacology 1987;26:679-91.
8. Matefy RE, Hayes C, Hirsh J. Psychedelic drug flashbacks: subjective reports and biographical data. Addict Behav 1978;3: 165-78.
9. Landau SI, Becker EL, Butterfield WJH, Harvey AM, Heptinstall RH, Thomas L. International dictionary of medicine and biology. New York: Wiley, 1986.
10. Slade PD. Towards a theory of auditory hallucinations: outline of an hypothetical four-factor model. Br J Soc Clin Psychol 1976; 15:415-23.
11. Skodol AE, Shrout PE. Use of DSM-III-R axis IV in clinical practice: rating etiologically significant stressors. Am J Psychiatry 1989;146:61-6.
12. Spielberger CD. Manual for the State-Trait Anxiety Inventory. Palo Alto, CA: Consulting Psychologist Press, 1983.
13. Monterio MG, Schuckit MA, Irwin M. Subjective feelings of anxiety in young men after ethanol and diazepam infusions. J Clin Psychiatry 1990;51:12-6.
14. Overall JF, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962;10:799-812.
15. Millns H, Woodward M, Bolton-Smith C. Is it necessary to transform nutrient variables prior to statistical analyses? Am J Epidemiol 1995;141:251-62.
16. Havilcek LL, Crain RD. Practical statistics for the physical sciences. Washington, DC: American Chemical Society, 1988.
17. Dimsdale JE, Moss J. Plasma catecholamines in stress and exercise. JAMA 1980;243:340-2.
18. Bell DS. Comparison of amphetamine psychosis and schizophrenia. Br J Psychiatry 1965;111:701-7.
19. Anisman H, Zacharko RM. Behavioral and neurochemical consequences associated with stressors. Ann N Y Acad Sci 1995;771: 205-25.
20. Ozawa A. Normal and abnormal values: catecholamines [in Japanese]. Sogorinsho [General Practice of Medicine] 1991;40:1332-8.
21. Liebowitz MR, Gorman JM, Fyer AJ, Levitt M, Dillon D, Levy G, Appleby IL, Anderson S, Palij M, Davies SO, Klein DF. Lactate provocation of panic attacks. Arch Gen Psychiatry 1985;42:709-19.
22. Nakai T. Catecholamines in urine and plasma. In: Nakai T, ed. Assessment of laboratory data [in Japanese]. Tokyo: Naigaiigakusya, 1996:411-2.
23. van Kammen DP, Docherty JP, Bunney WE. Prediction of early relapse after pimozide discontinuation by response to d-amphetamine during pimozide treatment. Biol Psychiatry 1982;2: 233-42.
24. Péronnet F, Blier P, Brisson G, Diamond P, Ledoux M, Volle M. Plasma catecholamines at rest and exercise in subjects with high-and low-trait anxiety. Psychosom Med 1986;48:52-8.
25. Wang MT, Yoshioka M, Imai K, Tamura Z. Gas-liquid chromatographic and mass fragmentographic determination of 3-O-methylated catecholamines in human plasma. Clin Chim Acta 1975;63: 21-7.
26. Heal DJ, Frankland ATJ, Buckett WR. A new and highly sensitive method for measuring 3-methoxytyramine using HPLC with electrochemical detention studies with drugs which alter dopamine metabolism in the brain. Neuropharmacology 1990;29:1141-50.
27. Wood PL, Altar A. Dopamine release in vivo from nigrostriatal, mesolimbic, and mesocortical neurons: utility of 3-methoxytyramine measurements. Pharmacol Rev 1988;40:163-87.
28. Kent AP, Stern GM, Webster RA. The effect of benserazide on the peripheral and central distribution and metabolism of levodopa after acute and chronic administration in the rat. Br J Pharmacol 1990;100:743-8.
29. Westerink BHC, Spaan SJ. On the significance of endogenous 3-methoxytyramine for the effects of centrally acting drugs on dopamine release in the rat brain. J Neurochem 1982;38:680-6.
30. Charpusta SJ, Wyatt RJ, Masserano JM. Effects of single and repeated footshock on dopamine release and metabolism in the brains of Fischer rats. J Neurochem 1997;68:2024-31.
31. Post RM. Cocaine psychosis: a continuum model. Am J Psychiatry 1975;132:225-31.
32. MacLennan AJ, Maier SF. Coping and the stress-induced potentiation of stimulant stereotypy in the rat. Science 1983;219:1091-3.
33. Hornykiewicz O. Brain catecholamines in schizophrenia: a good case for noradrenaline. Nature 1982;299:484-6.
34. van Kammen DP, Kelley M. Dopamine and norepinephrine activity in schizophrenia: an integrative perspective. Schizophr Res 1991;4:173-91.
35. Ziegler MG, Lake CR, Wood JH, Brooks BR, Ebert MH. Relationship between norepinephrine in blood and cerebrospinal fluid in the presence of a blood-brain barrier for norepinephrine. J Neurochem 1977;28:677-9.
36. Roy A, Pickar D, Jong JD, Karoum F, Linnoila M. Norepinephrine and its metabolites in cerebrospinal fluid, plasma, and urine. Arch Gen Psychiatry 1988;45:849-57.
37. Abercrombie ED, Jacobs BL. Single-unit response of noradrenergic neurons in the locus coeruleus of freely moving cats: 1. Acutely presented stressful and nonstressful stimuli. J Neurosci 1987;7:2837-43.
38. Green AI, Alam MY, Boshes RA, Waternaux C, Pappalardo KM, Fitzgibbon ME, Tsuang MT, Scildkraut JJ. Haloperidol response and plasma catecholamines and their metabolites. Schizophr Res 1993;10:33-7.
39. Tuck JR. Effects of chlorpromazine, thioridazine and haloperidol on adrenergic transmitter mechanisms in man. Eur J Clin Pharmacol 1973;6:81-7.
40. Breier A, Buchanan RW, Waltrip RW II, Listwak S, Holmes C, Goldstein DS. The effect of clozapine on plasma norepinephrine: relationship to clinical efficacy. Neuropsychopharmacology 1994; 10:1-7.
41. Brown AS, Gewirtz G, Harkavy-Friedman J, Cooper T, Brébion G, Amador XF, Malaspina D, Gorman JM. Effects of clozapine on plasma catecholamines and relation to treatment response in schizophrenia: a within-subject comparison with haloperidol. Neuropsychopharmacology 1887;17:317-25.
42. Risbo A, Jessen K, Hagelsten JO. Catecholamine response to the clinical use of alpha adrenergic receptor blocking agents. Acta Anaesthesiol Scand 1983;27:72-4.
43. Castellani S, Ziegler MG, van Kammen DP, Alexander PE, Siris S, Lake CR. Plasma norepinephrine and dopamine-β-hydroxylase activity in schizophrenia. Arch Gen Psychiatry 1982;39:1145-9.
44. VonVoigtlander PF, Burian MA, Althaus TS, Williams LR. Effects of chronic haloperidol on vitamin E levels and monoamine metabolism in rats fed normal and vitamin E deficient diets. Res Commun Chem Pathol Pharmacol 1990;68:343-52.